Here are three things to know.
1. Under the deal, Ipsen will acquire the rights to Prontalgine, an analgesic intended to treat moderate to severe pain. Sales for the drug, which is only available in France, increased at double-digit rates over the last four years, reports Reuters.
2. Ipsen will also acquire the antispasmodic treatment Buscopan, the laxative Suppositoria Glycerini and cough and flu products Mucothiol and Mucodyne, according to the report.
3. Sanofi is selling off the treatments as part of a requirement from the European Commission for a previous deal the drugmaker entered with Boehringer Ingelheim, according to the report.
More articles on supply chain:
Yale, Mayo Clinic to team up on medical regulation
Researchers call high cost of cancer drugs ‘unsustainable’
6 must-reads for supply chain leaders this week
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
